The National Comprehensive Cancer Network provides a list of preferred primary therapy regimens for transplant-eligible and nontransplant candidates and lists drugs recommended for maintenance therapy ...

NCCN consolidates MRD guidance on a new MYEL-E page, standardizing bone marrow–based MRD assessment using NGS or multicolor flow cytometry across the treatment continuum. Preferred analytical ...

Experts highlight updated findings from CARTITUDE-2, how to mitigate late toxicities, and other key considerations in the modern multiple myeloma landscape.

Adaptive Biotechnologies gains from new myeloma MRD guidelines, strong clonoSEQ growth, and refinancing tailwinds. Read why ...

"Dr. Rahul Banerjee joins the podcast to discuss the latest update to the living guideline on the treatment of multiple myeloma. He explains how sensational results from the MajesTEC-3 trial, which ...

Dr. Lisa Hicks and Dr. Joseph Mikhael discuss the updated guideline from ASCO and Ontario Health (Cancer Care Ontario) on the treatment of multiple myeloma. They cover recommendations for therapeutic ...

Matthew J. Frigault, MD, and Adam D. Cohen, MD, outline how updated NCCN guidelines position CAR T-cell therapy in early ...

Linvoseltamab-gcpt is now a preferred treatment for multiple myeloma after 4 prior therapies, joining other bispecific antibodies in the NCCN guidelines. The FDA granted accelerated approval to ...

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. Updated guidelines establish a dedicated framework ...

The best way to treat peripheral neuropathy (PN) in patients with multiple myeloma is to keep it from occurring in the first place, according to members of the International Myeloma Working Group ...

Advances in MM management have improved survival, but challenges remain for patients progressing after three therapy lines. New therapies like CAR T-cell and bispecific antibodies require integration ...